Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Russell

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
BJU International|April 13, 2013
Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trialChristopher C Parker, Matthew R Sydes, Malcolm D Mason, et al.
Health Technology Assessment (Winchester, England)|July 20, 2016
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancerNicholas James, Sarah Pirrie, Ann Pope, et al.
BJU International|September 24, 2017
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancerRobert J Rulach, Stephen McKay, Sam Neilson, et al.
Trials|September 18, 2012
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trialMatthew R Sydes, Mahesh K B Parmar, Malcolm D Mason, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
European Urology Oncology|September 7, 2021
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)John N Staffurth, Joanne S Haviland, Anna Wilkins, et al.
The Lancet. Oncology|November 3, 2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trialAnna Wilkins, Helen Mossop, Isabel Syndikus, et al.
JAMA Oncology|January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical TrialNicholas D James, Sarah J Pirrie, Ann M Pope, et al.
The Lancet. Oncology|March 4, 2014
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trialDavid P Dearnaley, Gordana Jovic, Isabel Syndikus, et al.
The Lancet. Oncology|May 8, 2007
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trialDavid P Dearnaley, Matthew R Sydes, John D Graham, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
BJU International|April 13, 2013
Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trialChristopher C Parker, Matthew R Sydes, Malcolm D Mason, et al.
Health Technology Assessment (Winchester, England)|July 20, 2016
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancerNicholas James, Sarah Pirrie, Ann Pope, et al.
BJU International|September 24, 2017
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancerRobert J Rulach, Stephen McKay, Sam Neilson, et al.
Trials|September 18, 2012
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trialMatthew R Sydes, Mahesh K B Parmar, Malcolm D Mason, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
European Urology Oncology|September 7, 2021
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)John N Staffurth, Joanne S Haviland, Anna Wilkins, et al.
The Lancet. Oncology|November 3, 2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trialAnna Wilkins, Helen Mossop, Isabel Syndikus, et al.
JAMA Oncology|January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical TrialNicholas D James, Sarah J Pirrie, Ann M Pope, et al.
The Lancet. Oncology|March 4, 2014
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trialDavid P Dearnaley, Gordana Jovic, Isabel Syndikus, et al.
The Lancet. Oncology|May 8, 2007
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trialDavid P Dearnaley, Matthew R Sydes, John D Graham, et al.
Pageof 4